Last reviewed · How we verify
JS107 for Injection
JS107 is a monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the brakes on T-cell activation.
JS107 is a monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the brakes on T-cell activation. Used for Non-small cell lung cancer, Other solid tumors (under investigation).
At a glance
| Generic name | JS107 for Injection |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
JS107 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 on T cells. This blockade restores T-cell proliferation, activation, and anti-tumor cytotoxic function. The mechanism is designed to overcome tumor immune evasion and promote durable anti-tumor immunity.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation)
Common side effects
- Fatigue
- Decreased appetite
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JS107 for Injection CI brief — competitive landscape report
- JS107 for Injection updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI